NCT07334535 2026-01-13
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
Clinical Trials
10 trialsNCT05722405 2026-01-05
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4 Recruiting
NCT03829371 2025-12-03
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
University of Turin, Italy
Phase 4 Active not recruiting
NCT07025005 2025-11-04
VRd MM Fibrate
Tanta University
Phase 4 Recruiting
NCT03934684 2025-08-06
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT06409702 2025-06-12
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
The First Affiliated Hospital of Soochow University
Phase 4 Recruiting
NCT04217967 2024-08-01
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
Peking Union Medical College Hospital
Phase 4 Completed
NCT05183139 2022-05-03
US MM-7
Takeda
Phase 4 Withdrawn
NCT04040491 2020-05-12
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
Zhengzhou University
Phase 4 Unknown
NCT01731886 2020-02-05
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Columbia University
Phase 4 Completed